IG
ING Group’s Charles River Laboratories CRL Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $981K | Sell |
6,463
-67
| -1% | -$10.2K | 0.01% | 403 |
|
|
2025
Q1 | $983K | Sell |
6,530
-1
| -0% | -$151 | 0.01% | 406 |
|
|
2024
Q4 | $1.21M | Sell |
6,531
-374
| -5% | -$69K | 0.01% | 479 |
|
|
2024
Q3 | $1.36M | Sell |
6,905
-27
| -0.4% | -$5.32K | 0.01% | 455 |
|
|
2024
Q2 | $1.43M | Sell |
6,932
-97
| -1% | -$20K | 0.01% | 469 |
|
|
2024
Q1 | $1.9M | Buy |
7,029
+6
| +0.1% | +$1.63K | 0.01% | 451 |
|
|
2023
Q4 | $1.66M | Buy |
7,023
+586
| +9% | +$139K | 0.01% | 424 |
|
|
2023
Q3 | $1.26M | Buy |
+6,437
| New | +$1.26M | 0.01% | 428 |
|
|
2023
Q2 | – | Sell |
-8,646
| Closed | -$1.74M | – | 572 |
|
|
2023
Q1 | $1.74M | Buy |
+8,646
| New | +$1.74M | 0.02% | 380 |
|
|
2022
Q4 | – | Sell |
-7,972
| Closed | -$1.57M | – | 524 |
|
|
2022
Q3 | $1.57M | Sell |
7,972
-1,588
| -17% | -$313K | 0.03% | 311 |
|
|
2022
Q2 | $2.05M | Buy |
9,560
+1,554
| +19% | +$333K | 0.02% | 393 |
|
|
2022
Q1 | $2.27M | Buy |
8,006
+1,419
| +22% | +$403K | 0.02% | 379 |
|
|
2021
Q4 | $2.48M | Buy |
6,587
+2,356
| +56% | +$888K | 0.02% | 436 |
|
|
2021
Q3 | $1.75M | Buy |
4,231
+104
| +3% | +$42.9K | 0.02% | 393 |
|
|
2021
Q2 | $1.53M | Buy |
+4,127
| New | +$1.53M | 0.02% | 368 |
|
|
2019
Q3 | – | Sell |
-7,473
| Closed | -$1.06M | – | 543 |
|
|
2019
Q2 | $1.06M | Buy |
7,473
+83
| +1% | +$11.8K | 0.02% | 372 |
|
|
2019
Q1 | $1.07M | Buy |
7,390
+18
| +0.2% | +$2.61K | 0.02% | 305 |
|
|
2018
Q4 | $834K | Buy |
7,372
+29
| +0.4% | +$3.28K | 0.02% | 364 |
|
|
2018
Q3 | $988K | Buy |
7,343
+4
| +0.1% | +$538 | 0.02% | 365 |
|
|
2018
Q2 | $824K | Buy |
7,339
+125
| +2% | +$14K | 0.02% | 359 |
|
|
2018
Q1 | $770K | Buy |
7,214
+68
| +1% | +$7.26K | 0.01% | 385 |
|
|
2017
Q4 | $782K | Buy |
7,146
+1,317
| +23% | +$144K | 0.01% | 385 |
|
|
2017
Q3 | $630K | Buy |
5,829
+35
| +0.6% | +$3.78K | 0.01% | 417 |
|
|
2017
Q2 | $586K | Buy |
+5,794
| New | +$586K | 0.01% | 436 |
|